Northwire Canada EditionSunday, October 18, 2026
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Earnings

Eupraxia ends Q3 with cash of $89-million (U.S.)

EPRX · Price

Executive Summary

  • Eupraxia Pharmaceuticals reported its Third Quarter 2025 financial results, including a net loss of $6.4 million and cash reserves of $89.0 million.
  • The company announced the closing of an $80.5 million public offering of common shares, priced at $5.50 per share, to fund clinical development of its lead asset, EP-104GI.
  • Positive 52-week data from the phase 1b/2a Resolve trial for EP-104GI (treating eosinophilic esophagitis) showed durable remission in two-thirds of patients in cohort 5, with top-line phase 2b data expected in Q3 2026.

Key Details

  • Financing Details:
    • Closed public offering of 14,636,363 common shares.
    • Price: $5.50 per common share.
    • Gross Proceeds: Approximately $80.5 million.
    • Includes full exercise of underwriter’s option to purchase 1,909,090 additional shares.
    • Use of Proceeds: Clinical development of EP-104GI and broader pipeline advancement.
  • Clinical Updates (EP-104GI for EoE):
    • Phase 1b/2a Resolve Trial: 52-week data released Sept 2, 2025.
    • Cohort 5 (N=3): Two-thirds of patients remained in clinical remission after one year of treatment.
    • Outcomes: Durable symptom and tissue responses beyond nine months; largest improvements in tissue health and eosinophil reduction observed to date; no new safety concerns.
    • Future Milestone: Top-line data from the phase 2b Resolve trial expected in Q3 2026.
    • Additional 52-week data from cohort 6 expected later in the year.
  • Financial Performance (Q3 2025):
    • Net Loss: $6.4 million (vs. $6.0 million in Q3 2024).
    • Loss Drivers: Increase in R&D and G&A costs, partially offset by increased other income.
    • Cash Position: $89.0 million as of Sept 30, 2025 (up from $33.1 million at end of Q4 2024).
    • Liquidity Outlook: Existing cash and anticipated warrant exercises sufficient to finance operations into H1 2028.
  • Capitalization:
    • Common Shares Outstanding: 50,598,331.
    • Preferred Shares Outstanding: 8,905,638.
  • Operational & Macro Context:
    • Tariffs: Management monitoring potential impacts of 25% US tariffs on Canadian goods and retaliatory Canadian tariffs.
    • Manufacturing: Clinical supplies for EP-104IAR and EP-104GI manufactured in the US by a third party; company expects continued access.
    • FX Strategy: Maintains USD balances to cover USD expenses and mitigate exchange rate fluctuations.

Notable Quotes

  • "The compelling 52-week data from our Resolve trial reported this quarter further reinforce the potential of EP-104GI as a highly effective and durable treatment for eosinophilic esophagitis (EoE)... Coupled with the successful completion of our $80.5-million financing supported by strong life science focused investors, we are now well resourced to advance the EP-104GI program..." — Dr. James Helliwell, CEO
Read the original news release →

More from Eupraxia Pharmaceuticals Inc